The results of a small, single-arm study conducted at the Ohio State University indicate that adminis­tering Darzalex using a time-saving 90-minute in­fusion protocol can be safe.

No patients in the study ex­peri­enced severe in­fusion-related reac­tions, and there was only one mild reac­tion in a patient who had no further reac­tions during sub­se­quent in­fusions at the 90-minute rate.

The faster Darzalex (dara­tu­mu­mab) in­fusion rate tested in the study is two hours shorter than the standard 3.5 hour rate. Patients in the study were receiving their third, or sub­se­quent, Darzalex in­fusions.

Infusion-related …